Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co pays €110m upfront for AiCuris' CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

Merck & Co has agreed an upfront payment of €110m (around $140m) to buy German biotech AiCuris' portfolio of drugs to treat human cytomegalovirus (CMV) infection.

In addition to this sum, Bayer spin-out AiCuris stands to receive up to €334.5m in development, regulatory, and commercialisation milestone payments, as well as royalties on sales.

The lead drug candidate covered by the deal is letermovir (AIC246), an orally-active compound which has successfully completed a phase IIb trial for the treatment and prevention of CMV infection in transplant patients.

Letermovir works by inhibiting an enzyme called CMV viral terminase, and Merck has also bought a follow-up compound targeting the same enzyme and various other phase I candidates that work in a different way.

Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA.

Dr Roger Pomerantz, head of infectious disease R&D at Merck Research Laboratories, said: "There is a significant need for additional medicines for the treatment of [CMV] infection, which is one of the most common viral infections affecting organ and bone marrow transplant patients."

"This portfolio complements Merck's broad antiviral portfolio," he added. Merck currently has two antiviral candidates in clinical testing, namely hepatitis C virus (HCV) protease inhibitor vaniprevir in phase III and follow-up MK-5172 in phase II.

This is the first major licensing deal for privately-held AiCuris, which was formed as a spin-out from Bayer's anti-infectives unit in 2006 and has already advanced seven compounds into the clinic.

In addition to its CMV portfolio, the company is also seeking licensing partners for a drug targeting Herpes simplex virus (HSV) called AIC316, also heading into phase III testing, as well as two immune modulators being developed for viral hepatitis and fibrosis and autoimmune diseases.

16th October 2012

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....